Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Patent
1997-11-12
2000-08-29
Brusca, John S.
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
4353201, 536 231, 536 235, 536 237, 536 2372, 536 241, C12N 1564, C12N 1534, C12N 1512
Patent
active
061107441
ABSTRACT:
The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.
REFERENCES:
patent: 5527676 (1996-06-01), Vogelstein et al.
Berkner Development of adenovirus vectors for the expression of heterologous genes. Biotechniques vol. 6 pp. 616-629, 1988.
Fang, Koch and Roth, "Diminishing adenovirus gene expression and viral replication by promoter replacement," J. Virol., 71(6):4798-4803, 1997.
Fang, Koch and Roth, "Replacing adenovirus E4 promoter with GAL4/TATA dramatically reduces viral gene expression," Cancer Gene Therapy, 3(6):S25, Abstract P-54, 1996.
International Search Report dated Apr. 20, 1998 (PCT/US97/20608)(INGN:033P).
Yeh et al., "Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit," J. Virol., 70(1):559-565, 1996.
Abel et al., "DNA elements responsive to auxin," (Review), Bioessays, 18(8):647-54, Aug. 1996.
Abel et al., "The PS-IAA4/5-like family of early auxin-inducible mRNAs in Arabidopsis thaliana," J. Mol. Biol., 251(4):533-49, Aug. 1995.
Adler et al., "UV irradiation and heat shock mediate JNK activation via alternate pathways," J. Biol. Chem., 270(44):26071-26077, 1995.
Ali-Osman et al., "Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases .alpha. and .beta., and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy," J. Cell. Biochem., 54:11-19, 1994.
Baker et al., "Suppression of human colorectal carcinoma cell growth by wild-type p53," Science, 249:912-915, Aug. 1990.
Baverstock and Will, "Evidence of the dominance of direct excitation of DNA in the formation of strand breaks in cells following irradiation," Int. J. Radiat. Biol., 55(4):563-568, 1989.
Bigner et al., "Cyogenetics of human brain tumors," Cancer Genet Cytogenet, 47:141-154, 1990.
Bigner et al., "Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas," J. Neuropathol. & Experimental Neurol., XL(3):201-229, May/Jun. 1981.
Brand and Perrimon, "Targeted gene expression as a means of altering cell fates and generating dominant phenotypes," Development, 118:401-415, 1993.
Braselmann et al., "A selective transcription induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins," Proc. Natl. Acad. Sci. USA, 90:1657-1661, Mar. 1993.
Clarke et al., "Thymocyte apoptosis induced by p53-dependent and independent pathways," Nature, 362:849-852, Apr. 1993.
Di Leonardo et al., "DNA damage triggers a prolonged p53-dependent G.sub.1 arrest and long-term induction of Cip1 in normal human fibroblasts," Genes & Dev., 8:2540-2551, 1994.
Donehower et al., "Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability," Genes and Development, 9:882-895, 1995.
El-Deiry et al., "WAF1/CIP1 is induced in p53-mediated G.sub.1 arrest and apoptosis," Cancer Research, 54:1169-1174, Mar. 1994.
El-Deiry et al., "WAF1, a potential mediator of p53 tumor suppression," Cell, 75:817-825, Nov. 1993.
Eliyahu et al., "p53--a potential suppressor gene?" J. Cell Biochem., Supp. 14C, 1990 UCLA Symposia on Molecular and Cellular Biology, Abstract 1030, Feb.-Mar. 1990.
Evans et al., "Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation," Cancer Research, 54:1596-1603, Mar. 1994.
Fanjul et al., "A new class of retinoids with selective inhibition of AP-1 inhibits proliferation," Nature, 372:107-111, Nov. 1994.
Fischer et al., "GAL4 activates transcription in Drosophila," Nature, 332:853-856, Apr. 1988.
Fraval et al., "Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from micrococcus luteus," Mutation Research, 51:121-132, 1978.
Fujiwara et al., "Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene," Cancer Research, 54:2287-2291, May 1994.
Gipp et al., "DNA damage induced in Ht-29 colon cancer cells by exposure to 1-methyl-2-nitrosoimidazole, a reductive metabolite of 1-methyl-2-nitroimidazole," Biochem. Pharmacol., Suppl., 42:S127-S133, 1991.
Gjerset et al., "Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53," Mol. Carcinogenesis, 14:275-285, 1995.
Hinds, P.W. "Biological consequences of mutation of the p53 proto-oncogene," a dissertation presented to the faculty of Princeton University in candidacy for the degree of Doctor of Philosophy, Oct. 1989.
Izumoto et al., "Homozygous deletions of p16.sup.INK4A /MTS1 and p15.sup.INK4B /MTS2 genes in glioma cells and primary glioma tissues," Cancer Letters, 97:241-247, 1995.
Jen et al., "Deletion of p16 and p15 genes in brain tumors," Cancer Research, 54:6353-6358, Dec. 1994.
Kaden et al., "High frequency of large spontaneous deletions of DNA in tumor-derived CHEF cells," Proc. Natl. Acad. Sci. USA, 86:2306-2310, Apr. 1989.
Kamb, "Cell-cycle regulators and cancer," Trends in Genetics 11(4):136-140, Apr. 1995.
Kashani-Sabat et al., "Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells," J. Biol. Chem., 265(19):11285-11288, Jul. 1990.
Kashani-Sabet et al., "Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil," Eur. J. Cancer, 26(3):383-390, 1990.
Kimler, "The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions," J. Neuro-Oncology, 20:103-109, 1994.
Krougliak and Graham, "Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants," Human Gene Therapy, 6:1575-1586, Dec. 1995.
Lane, "p53, guardian of the genome," Nature, 358:15-16, Jul. 1992.
Lee et al., "Molecular basis of tumor suppression by the human retinoblastoma gene," J. Cell. Biochem., (Supp. 14C, 1990 UCLA Symposia on Molecular & Cellular Biology, Abstract 1001, Feb.-Mar. 1990.
Levine et al., "The p53 growth suppressor gene," J. Cell Biochem., Supp. 14C, 1990 UCLA Symposia on Molecular & Cellular Biology, Abstract, 1029, Feb.-Mar. 1990.
Liu et al., "Cleavage of DNA by mammalian DNA topoisomerase II," J. Biol. Chem., 258(24):15365-15370, Dec. 1983.
Liu and Miller, "Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei," Proc. Natl. Acad. Sci. USA, 78(6):3487-3491, Jun. 1981.
Lotem and Sachs, "Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents," Blood, 82(4):1092-1096, Aug. 1993.
Lowe et al., "p53-dependent apoptosis modulates the cytotoxicity of anticancer agents," Cell, 74:957-967, Sep. 1993.
Lowe et al., "p53 status and the efficacy of cancer therapy in vivo," Science, 266:807-810, Nov. 1994.
Lukas et al., "Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16," Nature, 375:503-506, Jun. 1995.
Mercer et al., "Antiproliferative effects of wild type human p53," J. Cell. Biochem., Supp. 14C, 1990 UCLA Symposia on Molecular & Cellular Biology,
Fang Bingliang
Roth Jack A.
Board of Regents , The University of Texas System
Brusca John S.
LandOfFree
Diminishing viral gene expression by promoter replacement does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diminishing viral gene expression by promoter replacement, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diminishing viral gene expression by promoter replacement will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1248894